 |
Recombinant antibody construct against human CD30 and CD16A |
|---|---|
| Trade Name | |
| Orphan Indication | Hodgkin’s disease |
| USA Market Approval | USA |
| USA Designation Date | 2009-08-20 00:00:00 |
| Sponsor | Affimed GmbH;Technologie Park, Heidelberg,; |
| |
Recombinant antibody construct against human CD30 and CD16A |
|---|---|
| Trade Name | |
| Orphan Indication | Hodgkin’s disease |
| USA Market Approval | USA |
| USA Designation Date | 2009-08-20 00:00:00 |
| Sponsor | Affimed GmbH;Technologie Park, Heidelberg,; |